午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

?????

?????
????? ??? ???
?? ??:
174022-42-5
???:
?????
???(??):
?????
???:
Bevirimat
???(??):
BVM;PA-457;CS-1322;MPC-4326;FH 11327;Bevirimat;Bevirimat, >99%;Bevirimat(PA-457);Bevirimat 174022-42-5;BVM; MPC-4326; PA-457
CBNumber:
CB22498801
???:
C36H56O6
??? ??:
584.83
MOL ??:
174022-42-5.mol
MSDS ??:
SDS

????? ??

???
>263°C (dec.)
?? ?
662.7±40.0 °C(Predicted)
??
1.13±0.1 g/cm3(Predicted)
?? ??
Hygroscopic, -20°C Freezer, Under inert atmosphere
???
??????(?? ???), ???(?? ??, ??, ??? ??)
??? ??
??
??? ??
??? ??
?? ?? (pKa)
4.48±0.28(Predicted)
??
???? ?????
???
???

??

????? C??? ??, ??, ??

??

PA-457 is an inhibitor of HIV-1 virion maturation. It inhibits the cleavage of the Gag capsid (CA) precursor CA-SP1 to the mature CA protein. PA-457 inhibits the replication of drug-sensitive and -resistant clinical isolates of HIV-1 in isolated human peripheral blood mononuclear cells (PBMCs; mean IC50s = 10.3 and 7.8 nM, respectively). In vivo, it prevents replication of HIV-1 in SCID-hu Thy/Liv mice when administered at a dose of 100 mg/kg.

??

ChEBI: A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhib tors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.

?? ???

This first-in-class, natural product-based antiviral (FW = 584.83 g/mol; CAS 174022-42-5; Abbreviation: BVM), also known as 3-O-(3',3'- dimethylsuccinyl)betulinate (DSB), 3β-(3-carboxy-3-methyl-butanoyloxy)- lup-20(29)-en-28-oic acid, PA-457, and MPC-4326, is a novel HIV-1 maturation inhibitor that blocks proteolytic processing of the Gag capsid precursor (CA-SP1) into mature capsid (CA) protein. Bevirimat binds to the Gag polypeptide at the CA/SP1 cleavage site. The net result of BVM treatment is the release of immature, noninfectious viral particles. Despite its promising mode of action, about half of all patients have viruses containing genetic polymorphisms in the Gag SP1 (at positions 6 to 8) protein do not respond to BVM treatment.

????? ?? ?? ? ???

???

?? ??


????? ?? ??

???( 115)?? ??
??? ?? ??? ?? ?? ? ??
Hebei Weibang Biotechnology Co., Ltd
+8615531157085
abby@weibangbio.com China 8808 58
Hebei Mojin Biotechnology Co., Ltd
+86 13288715578 +8613288715578
sales@hbmojin.com China 12834 58
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070
product@chemlin.com.cn CHINA 3009 60
Shanghai Zheyan Biotech Co., Ltd.
18017610038
zheyansh@163.com CHINA 3619 58
Chengdu Greenpure Biopharma CO.,Ltd
18283602253; +8618283602253
jancyzheng@gcgreenpure.com China 953 58
Chengdu GLP biotechnology Co Ltd
028-87075086 13350802083
scglp@glp-china.com CHINA 1824 58
Chengdu Biopurify Phytochemicals Ltd.
+8618080483897
sales@biopurify.com China 3772 58
NanJing Spring & Autumn Biological Engineering CO., LTD.
+8613815430202
sale02@cqherb.com CHINA 376 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
career henan chemical co
+86-0371-86658258 +8613203830695
factory@coreychem.com China 29811 58

Copyright 2019 ? ChemicalBook. All rights reserved